CLOUDBREAK-B(02592),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02592 CLOUDBREAK-B

Not Yet Opened 01-21 16:08:56

2.660

+0.010

+0.38%

High2.690	Low2.620	Vol1.09M
Open2.660	D1 Closing2.650	Amplitude2.64%
Mkt Cap2.26B	Tradable Cap2.26B	Total Shares850.00M
T/O2.89M	T/O Rate0.13%	Tradable Shares850.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"CLOUDBREAK-B","latestPrice":2.66,"timestamp":1768982936008,"preClose":2.65,"halted":0,"volume":1089000,"delay":0,"changeRate":0.0037735849056604646,"floatShares":850000000,"shares":850000000,"eps":-0.208525,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"01-21 16:08:56","open":2.66,"high":2.69,"low":2.62,"amount":2894085,"amplitude":0.026415,"askPrice":2.66,"askSize":2000,"bidPrice":2.65,"bidSize":26500,"shortable":3,"etf":0,"ttmEps":-0.386,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769045400000},"marketStatusCode":0,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":2.65,"openAndCloseTimeList":[[1768959000000,1768968000000],[1768971600000,1768982400000]],"volumeRatio":0.472759,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02592/tweets","defaultTab":"tweets","newsList":[{"id":"1127281663","title":"CLOUDBREAK-B Grants 8 Million Restricted Share Units Under Post-IPO Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1127281663","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127281663?lang=en_us&edition=fundamental","pubTime":"2026-01-18 17:32","pubTimestamp":1768728720,"startTime":"0","endTime":"0","summary":"On January 16, 2026, the company announced that it has granted a total of 8 million restricted share units under its post-initial public offering equity incentive plan. These units, equivalent to 8...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2603969685","title":"Cloudbreak Pharma Grants 8 Million Restricted Share Units Under Post-IPO Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2603969685","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603969685?lang=en_us&edition=fundamental","pubTime":"2026-01-16 17:09","pubTimestamp":1768554563,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced the grant of restricted share units  under its Post-IPO Equity Incentive Scheme. The company will grant 5,000,000 RSUs to one employee and 3,000,000 RSUs to one service provider, with the grant date set for 16 January 2026. Any unvested RSUs will be forfeited if the grantee leaves the company or is found, in the company’s view, to have materially breached employment terms or failed to meet required performance standards. No financial assistance was provided to grantees to facilitate the purchase of shares under this scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service oper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL1SWYxM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1181823282","title":"CLOUDBREAK-B (02592) Has Fully Paid the Settlement Amount to Cedar Wealth According to the Terms and Conditions of the Settlement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1181823282","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181823282?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:36","pubTimestamp":1768480586,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced details regarding, among other matters, legal proceedings initiated by Cedar Wealth against the company's indirectly wholly-owned subsidiary, CLOUDBREAK Guangzhou. On...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2603024986","title":"Cloudbreak Pharma Settles Legal Proceedings with Cedar Wealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2603024986","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603024986?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:19","pubTimestamp":1768479573,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced the settlement of legal proceedings related to a dispute with Cedar Wealth. The case involved an asset preservation order on Cloudbreak Guangzhou, a wholly owned subsidiary, which froze approximately RMB2.55 million in its bank account following arbitration initiated by Cedar Wealth. The company stated that the settlement is not expected to have a material adverse impact on its overall business, operations, or cash flow. Business and operations remain normal, and shareholders are advised to exercise caution when dealing in the company’s shares. Further updates will be provided as appropriate in accordance with regulatory requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLbhr5LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2603608602","title":"Cloudbreak Pharma Inc -  Settlement of Legal Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2603608602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603608602?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:18","pubTimestamp":1768479532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1157588045","title":"CLOUDBREAK-B (02592): Court Orders Judicial Preservation of CLOUDBREAK Guangzhou's Bank Account at ICBC Until November 30","url":"https://stock-news.laohu8.com/highlight/detail?id=1157588045","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157588045?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:58","pubTimestamp":1767797915,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on January 6, 2026, CLOUDBREAK Biopharmaceutical Technology (Guangzhou) Co., Ltd., an indirect wholly-owned subsidiary, received a notice issued by the Guangzhou...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161121","BK1161","02592"],"gpt_icon":0},{"id":"2601046658","title":"BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 December","url":"https://stock-news.laohu8.com/highlight/detail?id=2601046658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601046658?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:57","pubTimestamp":1767797842,"startTime":"0","endTime":"0","summary":"BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 DecemberJan 7  - Cloudbreak Pharma Inc 2592.HK:UNIT RECEIVES COURT NOTICE DATED 24 DECEMBERCOURT ORDERS PRESERVATION OF CLOUDBREAK GUANGZHOU'S RMB2.55 MILLION ACCOUNT TILL NOV 30, 2026Further company coverage: 2592.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y816E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2601280170","title":"Court Freezes Cloudbreak Pharma Subsidiary’s Bank Account in Legal Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2601280170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601280170?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:47","pubTimestamp":1767797265,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Subsidiary Cloudbreak Guangzhou Faces Legal Proceedings and Asset Preservation Order. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL4qWTwM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2601801792","title":"Cloudbreak Pharma Inc - Court Orders Preservation of Cloudbreak Guangzhou's RMB2.55 Mln Account Till Nov 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601801792?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:47","pubTimestamp":1767797255,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y816E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2601962538","title":"Cloudbreak Pharma's US Unit Submits Application for Juvenile Myopia Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2601962538","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601962538?lang=en_us&edition=fundamental","pubTime":"2026-01-06 18:50","pubTimestamp":1767696614,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma's  US unit, ADS Therapeutics, submitted an investigational new drug application for CBT-009 to China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The clinical-stage ophthalmology biotechnology company developed the drug for the treatment of juvenile myopia in children and adolescents aged 5 to 19.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1120737026","title":"CLOUDBREAK-B (02592) Successfully Submits CBT-009 New Drug Clinical Trial Application to Drug Review Center","url":"https://stock-news.laohu8.com/highlight/detail?id=1120737026","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120737026?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:47","pubTimestamp":1767689220,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that its wholly-owned subsidiary, ADS Therapeutics LLC (ADS USA), incorporated in Delaware, United States, has successfully submitted a new drug clinical trial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","CBT","BK4090","BK1161"],"gpt_icon":0},{"id":"2601686779","title":"Cloudbreak Pharma Inc -  Unit Submitted Ind Application for Cbt-009 to Center for Drug Evaluation to Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2601686779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601686779?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:39","pubTimestamp":1767688761,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y616N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2601867179","title":"Cloudbreak Pharma Submits IND Application for CBT-009 to China CDE","url":"https://stock-news.laohu8.com/highlight/detail?id=2601867179","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601867179?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:38","pubTimestamp":1767688727,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced that its wholly-owned subsidiary, ADS Therapeutics LLC, has successfully submitted an Investigational New Drug  application for CBT-009 to the Center for Drug Evaluation  of the National Medical Products Administration  in China. This milestone marks a significant step in the clinical development process for CBT-009, paving the way for potential Phase III clinical trials in the Chinese market. The company will continue to monitor the evaluation progress and update shareholders and investors as appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong K","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL7wb7SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2601009050","title":"Cloudbreak Pharma's Cornerstone Investor to Extend IPO Share Lock-Up; Shares Plunge 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601009050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601009050?lang=en_us&edition=fundamental","pubTime":"2026-01-05 16:30","pubTimestamp":1767601825,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma  said its cornerstone investor, Wealth Strategy, will extend the lock-up undertakings for the shares it subscribed to during the firm's IPO to July 2, according to a Jan. 2 Hong Kong bourse filing.Shares of the clinical-stage ophthalmology biotechnology company were down nearly 16% in Monday afternoon trading.The lock-up period was supposed to expire Jan. 3, the filing said.As of Monday, Wealth Strategy holds over 15.5 million shares in the firm, or a 1.84% holding.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SMST","BK4600","MSOO","APED","MSDD","MSTY.UK","BK1161","IMST","SMI3.UK","MST","MSST","MTYY","MSTW","3LMI.UK","BK4023","BK4516","BK4596","LMI3.UK","3SMI.UK","09799","02592","BK4585","BK4595","MSTU","MSTY","BK4588","MSTP","09399","MSII","MSTK","07799","07399","MSTX","MSTZ","WNTR"],"gpt_icon":0},{"id":"1101251542","title":"Hong Kong Stocks Movement | CLOUDBREAK-B (02592) Plunges Over 18%, Hits New Listing Low as Lock-up Expires Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1101251542","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101251542?lang=en_us&edition=fundamental","pubTime":"2026-01-05 09:56","pubTimestamp":1767578203,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) plummeted more than 18%, hitting a new low since its listing at HKD 3.69 during the trading session. As of the time of writing, the stock was down 18.18%, trading at HKD 3.69,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"1113691420","title":"Cloudbreak-B (02592) Issues 1.785 Million Shares Under 2023 Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1113691420","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113691420?lang=en_us&edition=fundamental","pubTime":"2026-01-04 18:54","pubTimestamp":1767524050,"startTime":"0","endTime":"0","summary":"Cloudbreak-B (02592) announced that on January 3, 2026, it allotted and issued 1.785 million shares pursuant to its 2023 equity incentive plan.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2600090326","title":"Following recent decline, Cloudbreak Pharma Inc.'s (HKG:2592) top shareholder CEO Jinsong Ni sees holdings value drop by 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600090326","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600090326?lang=en_us&edition=fundamental","pubTime":"2026-01-03 08:17","pubTimestamp":1767399431,"startTime":"0","endTime":"0","summary":"Key Insights Cloudbreak Pharma's significant insider ownership suggests inherent interests in company's expansion The...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2592/cloudbreak-pharma-shares/news/following-recent-decline-cloudbreak-pharma-incs-hkg2592-top","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2592/cloudbreak-pharma-shares/news/following-recent-decline-cloudbreak-pharma-incs-hkg2592-top","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"1114669997","title":"CLOUDBREAK-B (02592): Cornerstone Investor Fucé Holdings Voluntarily Extends Lock-up Period","url":"https://stock-news.laohu8.com/highlight/detail?id=1114669997","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114669997?lang=en_us&edition=fundamental","pubTime":"2026-01-02 12:18","pubTimestamp":1767327496,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on January 1, 2026, the company received a voluntary undertaking letter from one of its cornerstone investors, Fucé Holdings Limited. Pursuant to this, Fucé...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1120732671","title":"Hong Kong Stock Movement | CLOUDBREAK-B (02592) Surges Over 9% Intraday as Largest Single Shareholder Vows to Extend Lock-up Period by Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1120732671","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120732671?lang=en_us&edition=fundamental","pubTime":"2025-12-31 10:36","pubTimestamp":1767148580,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) surged more than 9% during the trading session, and as of the time of writing, the stock was up 5.17% to HK$5.29, with a turnover of HK$15.25 million. On the news front,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"1168499401","title":"CLOUDBREAK-B (02592) Secures Lock-up Extension from Major Shareholder Water Lily","url":"https://stock-news.laohu8.com/highlight/detail?id=1168499401","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168499401?lang=en_us&edition=fundamental","pubTime":"2025-12-29 18:50","pubTimestamp":1767005430,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on December 29, 2025, the company received a voluntary undertaking letter from one of its single largest shareholders, Water Lily Consultants Inc. Water Lily has...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://cloudbreakpharma.com","stockEarnings":[{"period":"1week","weight":-0.1424},{"period":"1month","weight":-0.5391},{"period":"3month","weight":-0.4409},{"period":"6month","weight":-0.5343},{"period":"1year","weight":-0.7376},{"period":"ytd","weight":-0.4904}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":0.031},{"period":"3month","weight":0.0274},{"period":"6month","weight":0.032},{"period":"1year","weight":0.3293},{"period":"ytd","weight":0.0334}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Cloudbreak Pharma Inc. is a clinical-stage ophthalmology biotechnology company dedicated to the development of various treatments. The Company is focusing on the in-house discovery, development and commercialization of ophthalmic therapies. The Company has two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed. Its Core Product, CBT-001, is indicated for the treatment of pterygium (a benign proliferative ocular surface disease), and it has commenced a Phase III multi-regional clinical trial (MRCT) in the United States and China. Its Core Product, CBT-009, is indicated for the treatment of juvenile myopia (myopia in children and adolescents aged 5 to 19) and has completed Phase I/II clinical trials. Its other drug candidates are in a relatively early development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical-stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011.","exchange":"SEHK","name":"CLOUDBREAK-B","nameEN":"CLOUDBREAK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLOUDBREAK-B(02592),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLOUDBREAK-B(02592) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLOUDBREAK-B,02592,CLOUDBREAK-B股票,CLOUDBREAK-B股票老虎,CLOUDBREAK-B股票老虎国际,CLOUDBREAK-B行情,CLOUDBREAK-B股票行情,CLOUDBREAK-B股价,CLOUDBREAK-B股市,CLOUDBREAK-B股票价格,CLOUDBREAK-B股票交易,CLOUDBREAK-B股票购买,CLOUDBREAK-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLOUDBREAK-B(02592),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLOUDBREAK-B(02592) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}